Preimplantation Genetic Diagnosis May Pose Neurological Risks
By Medical News Today,
Medical News Today
| 07. 23. 2009
Preimplantation genetic diagnosis (PGD) has helped many couples conceive healthy children and is generally considered a safe practice. However, a new long-term analysis of PGD in mice suggests that this procedure may increase risks of weight gain and memory decline in adulthood.
PGD is used alongside assisted reproduction technologies to ensure couples that may be carriers of genetic disease (e.g. Ashkenazi Jews who have a high incidence of Tay-Sachs among their population) don't pass on defective genes to their children. While PGD is not believed to pose any serious health risks, the procedure does involve manipulating the developing embryo and no rigorous long-term studies have been carried out.
Ran Huo, Qi Zhou and colleagues used a mouse model to examine how a blastomere biopsy, as the key manipulation during the PGD procedure, could affect fetal, neonatal and adult development.
They found that there were no differences in embryo development prior to uterine implantation in the biopsied and control groups, which is consistent with results found in humans. However, following implantation, successful births from biopsied embryos were significantly lower than in...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...